Zocilurtatug pelitecan - ZAI Lab
Alternative Names: YL-212; ZL-1310; zociLatest Information Update: 10 Aug 2026
At a glance
- Originator ZAI Lab
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Yes - Neuroendocrine carcinoma; Small cell lung cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 03 Aug 2026 Zocilurtatug pelitecan - ZAI Lab receives Orphan Drug status for Neuroendocrine carcinoma in USA
- 30 Jun 2026 Zai Lab plans phase III trial in Small cell lung cancer (First-line therapy and greater, Combination therapy) in December 2026 (IV)(NCT07796100)
- 16 Jun 2026 Zocilurtatug pelitecan - ZAI Lab receives Orphan Drug status for Neuroendocrine carcinoma in European Union